Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 436.49 Million CNY | -50.93% |
| 2022 | 889.56 Million CNY | -25.67% |
| 2021 | 1.19 Billion CNY | 36.74% |
| 2020 | 875.24 Million CNY | 53.33% |
| 2019 | 570.82 Million CNY | 42.0% |
| 2018 | 401.97 Million CNY | 41.34% |
| 2017 | 284.41 Million CNY | 40.72% |
| 2016 | 202.11 Million CNY | 0.84% |
| 2015 | 200.44 Million CNY | 25.24% |
| 2014 | 160.04 Million CNY | 26.24% |
| 2013 | 126.78 Million CNY | 26.75% |
| 2012 | 100.02 Million CNY | 32.02% |
| 2011 | 75.76 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 284.76 Million CNY | 2118.32% |
| 2024 Q3 | 239.12 Million CNY | -10.69% |
| 2024 Q2 | 267.73 Million CNY | -5.98% |
| 2023 FY | 436.49 Million CNY | -50.93% |
| 2023 Q4 | 12.83 Million CNY | -91.22% |
| 2023 Q3 | 146.14 Million CNY | 80.48% |
| 2023 Q1 | 196.52 Million CNY | 1563.37% |
| 2023 Q2 | 80.97 Million CNY | -58.8% |
| 2022 Q3 | 125.29 Million CNY | -69.66% |
| 2022 FY | 889.56 Million CNY | -25.67% |
| 2022 Q2 | 412.94 Million CNY | 23.19% |
| 2022 Q1 | 335.2 Million CNY | 0.44% |
| 2022 Q4 | 11.81 Million CNY | -90.57% |
| 2021 FY | 1.19 Billion CNY | 36.74% |
| 2021 Q1 | 283.3 Million CNY | 14.31% |
| 2021 Q4 | 333.72 Million CNY | 37.37% |
| 2021 Q3 | 242.94 Million CNY | -27.87% |
| 2021 Q2 | 336.83 Million CNY | 18.89% |
| 2020 Q4 | 247.83 Million CNY | 32.68% |
| 2020 Q3 | 186.78 Million CNY | -27.1% |
| 2020 FY | 875.24 Million CNY | 53.33% |
| 2020 Q1 | 184.42 Million CNY | 20.61% |
| 2020 Q2 | 256.2 Million CNY | 38.92% |
| 2019 Q1 | 129.58 Million CNY | 34.87% |
| 2019 Q2 | 176.17 Million CNY | 35.96% |
| 2019 Q4 | 152.9 Million CNY | 36.34% |
| 2019 FY | 570.82 Million CNY | 42.0% |
| 2019 Q3 | 112.15 Million CNY | -36.34% |
| 2018 Q4 | 96.07 Million CNY | 0.14% |
| 2018 Q2 | 119.97 Million CNY | 33.34% |
| 2018 Q1 | 89.97 Million CNY | 11.14% |
| 2018 FY | 401.97 Million CNY | 41.34% |
| 2018 Q3 | 95.94 Million CNY | -20.03% |
| 2017 Q4 | 80.95 Million CNY | 48.7% |
| 2017 Q1 | 59.63 Million CNY | -5.17% |
| 2017 FY | 284.41 Million CNY | 40.72% |
| 2017 Q2 | 89.38 Million CNY | 49.89% |
| 2017 Q3 | 54.44 Million CNY | -39.09% |
| 2016 Q2 | 53.61 Million CNY | 14.33% |
| 2016 FY | 202.11 Million CNY | 0.84% |
| 2016 Q4 | 62.88 Million CNY | 62.38% |
| 2016 Q3 | 38.72 Million CNY | -27.77% |
| 2016 Q1 | 46.89 Million CNY | -27.96% |
| 2015 FY | 200.44 Million CNY | 25.24% |
| 2015 Q4 | 65.09 Million CNY | 49.22% |
| 2015 Q3 | 43.62 Million CNY | 3.13% |
| 2015 Q2 | 42.29 Million CNY | 11.82% |
| 2015 Q1 | 37.82 Million CNY | 0.0% |
| 2014 FY | 160.04 Million CNY | 26.24% |
| 2013 FY | 126.78 Million CNY | 26.75% |
| 2012 FY | 100.02 Million CNY | 32.02% |
| 2011 FY | 75.76 Million CNY | 0.0% |